GlobeNewswire

Financial Services Expert, Mike Smith, Joins Bain & Company’s European Private Equity Practice

Share

LONDON, Nov. 06, 2018 (GLOBE NEWSWIRE) -- Mike Smith, an expert in financial services and private equity, has joined Bain & Company as a partner in the firm’s Private Equity practice in Europe, the Middle East and Africa (EMEA). He is based in Bain & Company’s London office.

Mike, who has more than 20 years of management consulting expertise, has led teams through the various stages of the investment lifecycle. He is an expert in value creation execution, investment strategy, due diligence, transaction strategy and structuring, consortium management, post-merger integration, and IPOs.

In his new role, Mike will focus on broadening Bain & Company’s expertise within the financial services ecosystem, with a particular emphasis on due diligences and post-acquisitions. He will expand the firm’s capabilities in wholesale markets and deepen its work with private equity funds, including tapping into his prior experience to grow the business across both large-cap and mid-market private equity clients.

“Mike is an integral part of the firm’s growing Private Equity team,” said Christophe De Vusser, head of Bain & Company’s Private Equity practice in EMEA. “His extensive experience in investment and value creation strategy along with his focus on results will be an asset to our clients across the region. He will also play a key role in helping us build our financial services team in private equity, a growing sector of interest for many private equity investors.”

In addition to the financial services industry, Mike has worked with a wide range of blue-chip corporate clients and private equity funds in the technology, information services, business services, and infrastructure sectors.

“Bain & Company is widely recognized as the leading advisory firm to the private equity sector,” said Mr. Smith. “I’m excited to join such a well-known, well-regarded team and look forward to helping our clients be successful across a wider range of transaction and strategic themes.” 

Prior to joining Bain & Company in 2018, Mike was a partner with Oliver Wyman in London.

He received his degree in manufacturing engineering (MET) from the University of Cambridge.

Editor's Note: To arrange an interview, contact Dan Pinkney at dan.pinkney@bain.com or +1 646 562 8102

About Bain & Company’s Private Equity Business
Bain & Company is the leading consulting partner to the private equity (PE) industry and its stakeholders. Private equity consulting at Bain & Company has grown thirteen-fold over the past 15 years and now represents about one-quarter of the firm’s global business. Bain & Company maintains a global network of more than 1,000 experienced professionals serving PE clients. The firm’s practice is more than triple the size of the next-largest consulting firm serving PE firms.

Bain & Company’s work with PE firms spans fund types – buyout, infrastructure, real estate and debt, as well as hedge funds – and many of the most prominent institutional investors, such as sovereign wealth funds, pension funds, endowments and family investment offices. Bain & Company supports its clients across a broad range of objectives that include deal generation, due diligence, immediate post-acquisition, ongoing value addition, exit, firm strategy and operations, and institutional investor strategy.

About Bain & Company
Bain & Company is the management consulting firm that the world's business leaders come to when they want results. Bain advises clients on strategy, operations, information technology, organization, private equity, digital transformation and strategy, and mergers and acquisition, developing practical insights that clients act on and transferring skills that make change stick. The firm aligns its incentives with clients by linking its fees to their results. Bain clients have outperformed the stock market 4 to 1. Founded in 1973, Bain has 57 offices in 36 countries, and its deep expertise and client roster cross every industry and economic sector. For more information visit: www.bain.com. Follow us on Twitter @BainAlerts.

Media Contact:
Dan Pinkney
Bain & Company
Tel: +1 646 562 8102
dan.pinkney@bain.com

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Inventiva secures new patent in the US strengthening the protection of its lead product candidate lanifibranor20.8.2019 17:45:00 CESTPress release

Inventiva secures new patent in the US strengthening the protection of its lead product candidate lanifibranor New patent granted in the United States by the USPTO protects the use of lanifibranor for the treatment of fibrotic diseases until June 2035 This patent strengthens the protection of lanifibranor in the United States Daix (France), August 20, 2019 – Inventiva (Euronext: IVA), a clinical-stage biopharmaceutical company developing oral small molecule therapies for the treatment of diseases in the areas of fibrosis, lysosomal storage disorders and oncology, today announced that the United States Patent and Trademark Office (USPTO) granted a new patent on August 20, 2019 that protects the use of lanifibranor for the treatment of fibrotic diseases until June 2035. This new patent further strenghens Inventiva’s patent portfolio for lanifibranor, the Company’s lead product candidate, in the United States, which already comprised a New Chemical Entity (NCE) patent and a patent protect

PCI Biotech: Invitation to second quarter and first half 2019 results presentation20.8.2019 15:38:00 CESTPress release

Oslo, Norway, 20 August 2019 - PCI Biotech invites to a presentation of the company's second quarter and first half 2019 results on Wednesday 28 August 2019 at Oslo Cancer Cluster Innovation Park. Time: Wednesday 28 August, 08:30am – 09:30am CEST (local time). Venue: Jónas Einarsson aud. (2nd floor, entrance 2B), Oslo Cancer Cluster Innovation Park, Ullernchausséen 64, Oslo. The presentation will be held in English and if you wish to attend the presentation, please confirm with an e-mail to post@pcibiotech.com. The presentation will also be a live webcast and can be accessed through www.pcibiotech.com. It will be possible to post questions through the webcast console. The interim report and the presentation will be available on www.newsweb.no and on the company's webpage, www.pcibiotech.com from 07:00am (CEST) on 28 August 2019. For further information, please contact: Ronny Skuggedal, CFO Email: rs@pcibiotech.no Mobile: +47 9400 5757 About PCI Biotech PCI Biotech is a biopharmaceutica

Regarding resignation of member of the Supervisory Board20.8.2019 15:30:00 CESTPress release

We hereby inform that, T. Lukoševičius, a member of Supervisory Board of AB Klaipedos nafta (hereinafter – the Company) 20 August 2019 submitted a notice of resignation of members of Supervisory Board of the Company as of 3 September 2019 (this day is the last day of the mandate). It should be noted that, currently the Supervisory Board of the Company consists of 3 members, 2 of them are independent. After the resignation of T. Lukoševičius, the Ministry of Energy of the Republic of Lithuania will conduct the selection of new member of the Supervisory Board. The Supervisory Board is elected by the General Meeting of Shareholders for 4 years. If individual members of the Supervisory Board are elected, they shall be elected only until the end of the term of office of the current Supervisory Board. Jonas Lenkšas, Chief Financial Officer,+370 694 80594

SERSTECH AB: Boardmember Anna Werntoft resigns from the Board of Serstech20.8.2019 13:40:00 CESTPress release

Anna Werntoft will leave the board of directors effective on the 30th of September. The reason for her resignation is that she enters a new operational position with terms that does not allow external assignments. Serstech wishes Anna all the best in her new position and would like to thank her for her contribution while being on the Serstech Board. The Serstech will consist of three Board members until the vacant position is filled. The search for a replacement has started and will be concluded before the next annual general meeting. For further information, please contact: Stefan Sandor, CEO, Serstech AB tel: +46 739 606067 email: ss@serstech.com Thomas Pileby, Chairman of the Board, Serstech AB tel: +46 702 072643 email: tp@serstech.com Company website: www.serstech.com The information was submitted for publication, through the agency of the contact person set out above at 13:40 CET on August 20, 2019. Certified advisor to Serstech is Västra Hamnen Corporate Finance AB, phone: 040-2